Argenx
ARGX
#454
Rank
NZ$87.35 B
Marketcap
NZ$1,412
Share price
1.92%
Change (1 day)
20.80%
Change (1 year)
Argenx is a Dutch company that develops antibody therapies to fight autoimmune diseases and cancer.

EPS for Argenx (ARGX)

EPS in 2025 (TTM): NZ$15.24

According to Argenx 's latest financial reports the company's current EPS (TTM) is NZ$14.70. In 2024 the company made an earnings per share (EPS) of NZ$23.07 an increase over its 2023 EPS that were of NZ-$8.55.

EPS history for Argenx from 2011 to 2025

Annual EPS

Year EPS Change
2025 (TTM)NZ$15.24-33.94%
2024NZ$23.07-369.77%
2023NZ-$8.55-60.46%
2022NZ-$21.6363.33%
2021NZ-$13.24-40.37%
2020NZ-$22.21183.47%
2019NZ-$7.83123.09%
2018NZ-$3.5154.93%
2017NZ-$2.2714.07%
2016NZ-$1.9913.05%
2015NZ-$1.76-36.34%
2014NZ-$2.76209.04%
2013NZ-$0.89-33.99%
2012NZ-$1.35185.59%
2011NZ-$0.47